Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery

NCT01696955 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

81

Enrollment

NIH

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Carcinoma

Interventions

BIOLOGICAL: Cetuximab
OTHER: Laboratory Biomarker Analysis
DRUG: Tivantinib

Sponsor

National Cancer Institute (NCI)